Plasmapheresis Rescue Therapy in Progressive Systemic ANCA-Associated Vasculitis: Single-Center Results of Stepwise Escalation of Immunosuppression

被引:33
作者
de Joode, Anoek A. E. [1 ]
Sanders, Jan S. F. [1 ]
Smid, W. Martin [2 ]
Stegeman, Coen A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands
[2] Clin Consulting, Sanquin Blood Supply, Groningen, Netherlands
关键词
apheresis; auto-immunity; granulomatosis with polyangiitis; microscopic polyangiitis; SMALL-VESSEL VASCULITIS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; DIFFUSE ALVEOLAR HEMORRHAGE; PLASMA-EXCHANGE; RENAL VASCULITIS; WEGENERS-GRANULOMATOSIS; GLOMERULONEPHRITIS; METHYLPREDNISOLONE; MAINTENANCE; REMISSION;
D O I
10.1002/jca.21318
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We evaluated 26 patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) with progressive disease despite treatment with cyclophosphamide and steroids treated with additional plasmapheresis and compared outcome with 50 matched-disease controls. Methods: Patients diagnosed with AAV and treated with cyclophosphamide from January 1990 to December 2009 (n=272) were included when plasmapheresis was not started at diagnosis but added for progressive disease during initial standard therapy (n=26). We selected controls equal for age, Birmingham vasculitis activity score, and creatinine at diagnosis. Primary endpoint was estimated glomerular filtration rate (eGFR) or death. Results: Plasmapheresis was added 18 days (range 5-41) after start of therapy. In 11 patients, a rise in serum creatinine >30% led to plasmapheresis; insufficient response to induction (n=11), progressive pulmonary disease (n=3), or progressive necrotic lesions (n=1) were other indications.In the plasmapheresis group, six patients were in need of renal replacement therapy (RRT), and three controls. Five years after diagnosis, four patients had died in the plasmapheresis against eight controls (P=0.94). At baseline, mean eGFR was 44 ml/min/1.73 m(2) in plasmapheresis group versus 43 ml/min/1.73 m(2) in controls. At start of plasmapheresis, eGFR was 26 ml/min/1.73 m(2) (P=0.003), at 6 months mean eGFR had significantly improved to 44 ml/min/1.73 m(2) (P=0.0003), comparable to eGFR in controls, 48 ml/min/1.73 m(2). During long-term follow-up, there was no difference in renal function between the groups. Conclusion: AAV patients with progressive disease despite standard induction therapy in whom plasmapheresis was added had significant improvement in renal function and similar long-term outcome in both renal and patient survival as matched disease controls. J. Clin. Apheresis 29:266-272, 2014. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:266 / 272
页数:7
相关论文
共 20 条
[1]   Role of Plasmapheresis Performed in Hemodialysis Units for the Treatment of Anti-Neutrophilic Cytoplasmic Antibody-Associated Systemic Vasculitides [J].
Aydin, Zeki ;
Gursu, Meltem ;
Karadag, Serhat ;
Uzun, Sami ;
Tatli, Emel ;
Sumnu, Abdullah ;
Ozturk, Savas ;
Kazancioglu, Rumeyza .
THERAPEUTIC APHERESIS AND DIALYSIS, 2011, 15 (05) :493-498
[2]  
Falk RJ, 1997, J AM SOC NEPHROL, V8, P314
[3]  
Gregersen JW, 2012, CLIN EXP RHEUMATOL, V30, pS39
[4]   Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis [J].
Hagen, EC ;
Daha, MR ;
Hermans, J ;
Andrassy, K ;
Csernok, E ;
Gaskin, G ;
Lesavre, P ;
Lüdemann, J ;
Rasmussen, N ;
Sinico, RA ;
Wiik, A ;
van der Woude, FJ .
KIDNEY INTERNATIONAL, 1998, 53 (03) :743-753
[5]   Clinical management and treatment of vasculitis [J].
Jayne, D .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2001, 23 (03) :267-286
[6]   Randomized trial of plasma exchange or high-dosage Methylprednisolone as adjunctive therapy for severe renal vasculitis [J].
Jayne, David R. W. ;
Gaskin, Gill ;
Rasmussen, Niels ;
Abramowicz, Daniel ;
Ferrario, Franco ;
Guillevin, Loic ;
Mirapeix, Eduardo ;
Savage, Caroline O. S. ;
Sinico, Renato A. ;
Stegeman, Coen A. ;
Westman, Kerstin W. ;
van der Woude, Fokko J. ;
van Wijngaarden, Robert A. F. de Lind ;
Pusey, Charles D. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (07) :2180-2188
[7]   Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis [J].
Klemmer, PJ ;
Chalermskulrat, W ;
Reif, MS ;
Hogan, SL ;
Henke, DC ;
Falk, RJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (06) :1149-1153
[8]   Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis [J].
Lionaki, Sofia ;
Falk, Ronald J. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (07) :1987-1989
[9]   Therapeutic plasma exchange in systemic vasculitis: an update on indications and results [J].
Mahr, Alfred ;
Chaigne-Delalande, Severin ;
De Menthon, Mathilde .
CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (03) :261-266
[10]   Plasmapheresis for diffuse alveolar hemorrhage in a patient with Wegener's granulomatosis: Case report and review of the literature [J].
Nguyen, T ;
Martin, MK ;
Indrikovs, AJ .
JOURNAL OF CLINICAL APHERESIS, 2005, 20 (04) :230-234